PARP2

Poly [ADP-ribose] polymerase 2

74,114 patent compounds predicted against PARP2, 44,574 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tricyclazole (SCHEMBL23082)	0.66	16/20
SCHEMBL165829	1.00	8/20
SCHEMBL377729	0.60	8/20
SCHEMBL94920	0.52	8/20
Amentoflavone (SCHEMBL312563)	0.77	7/20
SCHEMBL120737	0.61	7/20
SCHEMBL162259	0.53	7/20
SCHEMBL378476	0.62	6/20
SCHEMBL205447	0.62	6/20
SCHEMBL205995	0.61	6/20
SCHEMBL207414	0.61	6/20
SCHEMBL316853	0.60	6/20
SCHEMBL316854	0.60	6/20
SCHEMBL204716	0.58	6/20
SCHEMBL205900	0.55	6/20
SCHEMBL204105	0.54	6/20
SCHEMBL205127	0.54	6/20
SCHEMBL377657	0.53	6/20
SCHEMBL164147	0.53	6/20
SCHEMBL204471	0.52	6/20

Germline variants in PARP2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PARP2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PARP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments	PHASE3	COMPLETED
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	PHASE2	COMPLETED
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)	PHASE1/PHASE2	RECRUITING
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors	PHASE1	COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer	PHASE1	COMPLETED
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer	PHASE1	COMPLETED
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a PARP2 binder may also engage these)

Protein	Name	Similarity
O88554	—	0.998	O88554 →
P31669	—	0.986	P31669 →
P27008	—	0.983	P27008 →
PARP3	Protein mono-ADP-ribosyltransferase PARP3	0.982	landscape →
Q3ULW8	—	0.981	Q3ULW8 →
Q9ZP54	—	0.980	Q9ZP54 →
Q5Z8Q9	—	0.980	Q5Z8Q9 →
O50017	—	0.980	O50017 →
Q9ZSV1	—	0.980	Q9ZSV1 →
P26446	—	0.979	P26446 →
P11103	—	0.979	P11103 →
Q11208	—	0.979	Q11208 →
Q7SXS8	—	0.979	Q7SXS8 →
P18493	—	0.979	P18493 →
Q5ZJM3	—	0.978	Q5ZJM3 →
P97386	—	0.977	P97386 →
Q803R5	—	0.977	Q803R5 →
Q5E9U4	—	0.977	Q5E9U4 →
Q14AI0	—	0.977	Q14AI0 →
Q32PL8	—	0.977	Q32PL8 →
Q8BJ37	—	0.976	Q8BJ37 →
A7Z050	—	0.976	A7Z050 →
P54276	—	0.976	P54276 →
P51612	—	0.976	P51612 →
Q6DDS9	—	0.976	Q6DDS9 →
Q5M9G7	—	0.976	Q5M9G7 →
Q0JMY1	—	0.976	Q0JMY1 →
PARP1	Poly [ADP-ribose] polymerase 1	0.975	landscape →
Q9R152	—	0.975	Q9R152 →
Q7EYV7	—	0.975	Q7EYV7 →